POS1062 THERAPEUTIC POTENTIAL OF IMVOTAMAB, A CD20-TARGETED BISPECIFIC IGM T CELL ENGAGER, FOR THE TREATMENT OF REFRACTORY AUTOIMMUNE DISEASE PATIENTSRacquel Domingo-Gonzalez, M. Harler, Miho Oyasu et al.|Annals of the Rheumatic Diseases|2024Cited by 9